Novo Nordisk Says Wegovy Reduces BMI in Children With Obesity in Phase 3 Trial

MT Newswires Live00:42

Novo Nordisk (NVO) said Monday that Wegovy demonstrated a reduction in body mass index, or BMI, among children with obesity aged 6 to under 12 in a phase 3 trial.

When combined with a reduced-calorie diet and increased physical activity, semaglutide led to a 17.4% reduction in BMI compared with a 2.2% increase with placebo after 68 weeks, the company said.

The company added that 83% of children receiving semaglutide improved their BMI category, compared with 23.5% in the placebo group.

The results were presented at a scientific symposium during ObesityWeek 2026 and simultaneously published in The New England Journal of Medicine, the company said.

Price: 41.84, Change: +0.20, Percent Change: +0.49

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment